References
- GishRGHepatocellular carcinoma: overcoming challenges in disease managementClin Gastroenterol Hepatol20064325226116527686
- CabreraRNelsonDRReview article: the management of hepatocellular carcinomaAliment Pharmacol Ther201031446147619925500
- BruixJShermanMPractice Guidelines Committee, American Association for the Study of Liver DiseasesManagement of hepatocellular carcinomaHepatology20054251208123616250051
- BruixJShermanMAmerican Association for the Study of Liver DiseasesManagement of hepatocellular carcinoma: an updateHepatology20115331020102221374666
- VerslypeCVan CutsemEDicatoMThe management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008Ann Oncol200920Suppl 7vii1vii619497945
- LiangPWangYMicrowave ablation of hepatocellular carcinomaOncology200772Suppl 112413118087193
- LlovetJMRealMIMontañaXArterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialLancet200235993191734173912049862
- LoCMNganHTsoWKRandomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology20023551164117111981766
- LlovetJMBruixJSystematic review of randomized trials for unresect-able hepatocellular carcinoma: Chemoembolization improves survivalHepatology200337242944212540794
- SalemRLewandowskiRJKulikLRadioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinomaGastroenterology20111402:497507 e221044630
- ChengALKangYKChenZEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialLancet Oncol2009101253419095497
- LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
- ChengAKangYLinDPhase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)J Clin Oncol201129Suppl Abstr 4000
- JohnsonPQinSWPJBrivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): results from the phase 3 BRISK-FL study [abstract LB-6]Proceedings of the 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9–13, 2012Boston, MA, USA
- Van CleaveJDevinePOdom-BallPMultidisciplinary care of hepatocellular carcinomaCancer Pract19997630230810732528
- BurakKWKnetemanNMAn evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithmCan J Gastroenterol2010241164365021157578
- ChangTTSawhneyRMontoAImplementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survivalHPB (Oxford)200810640541119088925
- FennellMLDasIPClauserSPetrelliNSalnerAThe organization of multidisciplinary care teams: modeling internal and external influences on cancer care qualityJ Natl Cancer Inst Monogr2010201040728020386055
- GishRGLencioniRDi BisceglieAMRaoulJLMazzaferroVRole of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinomaExpert Rev Gastroenterol Hepatol20126217318522375523